Topaz raises $20M in first round

Philadelphia-based Topaz Pharmaceuticals has raised $20 million in Series A financing from Aisling Capital and Fidelity Biosciences. The funds will be used to help Topaz complete clinical trials of the company's new prescription medicine to fight head lice, which are becoming more resistant to some traditional treatments. The funding will also be used to prepare the product for market.

- check out the release from Topaz

ALSO: Cambridge, MA-based Merrimack Pharmaceuticals has raised $35 million of an $80 Series F financing round. Investors in the round were not disclosed. Report

PLUS: Evalve, a developer devices for the percutaneous repair of cardiac valves, has completed a $60 million Series D financing. Release

Related Articles:
Billion-dollar baby: Biotech still on a roll with VC funds. Report
Venture capitalists bet big on nanotechnology. Report
Bill could improve funding for small biotechs. Report